Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide and Insulin Glargine in the context of fatty liver & elevated liver enzymes.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.

How the Study Was Run

The design is described as randomized and multicenter.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Running at several centres spread the Exenatide study over different clinics and patient groups.

The researchers performed a 24-week randomized controlled multicentre clinical trial.

The endpoints included changes in liver fat content (LFC), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) measured by magnetic resonance spectroscopy, blood glucose, liver enzymes, lipid profile, body weight, and Fibrosis-4 index (FIB-4).

What Was Measured

The subject headings attached to it are Biomarkers, Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hypoglycemic Agents and Insulin Glargine.

Author keywords: glucagon-like peptide-1 receptor agonist, liver fat content, nonalcoholic fatty liver disease and type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exenatide and Insulin Glargine in people with fatty liver & elevated liver enzymes.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Exenatide compound page and the Insulin Glargine compound page, Fatty liver & elevated liver enzymes research.